There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Closed, Sticky:
A brief review of recent ChIP-Seq tools literature
|
20 responses
88,656 views
0 reactions
|
by sameet
04-26-2010, 04:40 PM
|
||
|
4 responses
3,232 views
0 reactions
|
by simonandrews
11-26-2013, 01:36 AM
|
|||
|
9 responses
3,725 views
0 reactions
|
by genefan
11-19-2013, 12:07 AM
|
|||
|
5 responses
2,999 views
0 reactions
|
by dpryan
11-08-2013, 01:53 AM
|
|||
|
4 responses
6,655 views
0 reactions
|
by bioinfo816
11-07-2013, 07:20 PM
|
|||
|
9 responses
8,310 views
0 reactions
|
by metheuse
11-06-2013, 06:10 AM
|
|||
|
2 responses
2,074 views
0 reactions
|
by metheuse
10-22-2013, 09:28 AM
|
|||
|
0 responses
1,818 views
0 reactions
|
by pmad
10-21-2013, 04:12 PM
|
|||
|
0 responses
2,869 views
0 reactions
|
by pmad
10-21-2013, 04:04 PM
|
|||
|
8 responses
10,278 views
0 reactions
|
by pmiguel
10-18-2013, 08:04 AM
|
|||
|
0 responses
2,225 views
0 reactions
|
by puggie
10-08-2013, 06:42 AM
|
No topics found.
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
-
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...Today, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
-
I’m not a sequencing expert. I’m a purification scientist who uses NGS to evaluate workflows my group develops. With this perspective, we think about the sample first and the NGS workflow second. The sequencer is an exceptionally honest reporter, but it can only report on what you give it, so whether you get clean, interpretable data from an NGS workflow is largely determined before you begin.
Here are nine questions we think about, in roughly the order they matter, before...